)
Inhibikase Therapeutics (IKT) investor relations material
Inhibikase Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Phase III program and milestones
Phase III launched; 28 countries approved and 79 sites active within the prior 4–6 months, with execution meeting internal expectations.
H1 2027 safety update expected after 50 patients have 12 weeks of data; planned disclosure is limited to DSMB review and confirmation the trial can continue, tied to a $55M financing tranche.
Mid-2028 Part A: 140 patients, powered for primary PVR endpoint; six-minute walk and other secondary data also expected.
Mid-2029 pivotal Part B data expected; target enrollment is 340 patients, with Part A and B using the same sites and providing independent data sets for a potential filing package.
Efficacy and product profile
IKT-001 is a prodrug designed to remain intact in the GI tract before converting to imatinib in plasma; expected to retain imatinib-like efficacy.
Management views a 20% PVR reduction and 20-meter six-minute-walk improvement as clinically meaningful; hopes and expectations are closer to IMPRES results of ~30% reductions and ~30-meter improvement.
Part A six-minute-walk results are expected to show trends, but the 140-patient segment is not powered for statistical significance on that measure.
Safety and dosing approach
Preclinical work suggests lower GI effects than imatinib; clinical studies will test this. Systemic imatinib-associated effects, including edema, are still expected.
Planned titration to higher dose takes eight weeks; 300, 400 and 500 mg doses are available, with investigator and patient discretion to step down if needed to support trial retention.
Protocol training distinguishes edema from clinical worsening; multiple criteria define worsening events, addressing a concern raised in IMPRES.
- IKT-001 pairs imatinib’s PAH efficacy potential with a redesigned Phase 3 program.IKT
Corporate presentation - IMPROVE-PAH advanced as $193.3M in liquidity supported development amid rising losses.IKT
Q3 2026 - IKT-001 targets PAH with strong efficacy, improved tolerability, and global Phase 3 enrollment underway.IKT
Corporate presentation - IKT-001 targets PAH with improved tolerability and efficacy; Phase 3 topline data expected 2029.IKT
Corporate presentation - Phase 3 PAH trial advances, Orphan Drug Designation secured, and $50M raised in July 2026.IKT
Q2 2026 - Q1 2026 net loss reached $16.4M as global Phase 3 PAH trial enrollment and spending increased.IKT
Q1 2026 - Director elections, auditor ratification, and equity plan amendments headline the annual meeting.IKT
Proxy filing - Virtual annual meeting to vote on directors, auditor, equity plan, and executive pay proposals.IKT
Proxy filing - Virtual meeting to vote on directors, auditor, equity plan, and executive compensation matters.IKT
Proxy filing
)
)
)
)
)
)
)
)